Ulcerative Colitis
Quality improvement program produces better IBD outcomes
Top stories in gastroenterology: Fibrosis risk highest in young adults with alcohol use disorder, colorectal cancer spikes around age 50 years
Highlights from Crohn’s and Colitis Congress 2020
Chinese herb reduces risk for recurrent colorectal adenoma, plus more top stories in gastroenterology
VIDEO: Patient-reported outcome system may help ‘drill down’ QOL issues after IPAA
AUSTIN, Texas — In this exclusive video from Crohn’s & Colitis Congress, Edward L. Barnes, MD, MPH, assistant professor of medicine at the University of North Carolina at Chapel Hill, discusses the results of a study he and colleagues presented that showed how patients with recent pouchitis had significant reductions in specific areas of social, emotional and physical health.
VIDEO: Start with the ‘basics’ when positioning therapies for UC
AUSTIN, Texas — In this exclusive video from Crohn’s & Colitis Congress, James Lindsay, PhD, FRCP, professor of inflammatory bowel disease at Barts and the London School of Medicine and Dentistry, Queen Mary University of London and a consultant gastroenterologist at Barts Health NHS Trust, discusses positioning therapies in ulcerative colitis.
Sibling donation of FMT linked to long-term UC remission
AUSTIN, Texas — The use of sibling donation for fecal microbiota transplant led to long-term remission of ulcerative colitis more often than donation from a parent, according to a presenter at the Crohn’s and Colitis Congress. Additionally, when donor and recipient were close in age – less than 10 years difference – researchers saw greater success.
Diet-as-therapy in IBD relies on shared decision-making, compliance
Proctocolectomy doubles 30-day readmission risk vs. colectomy alone
Choosing a roster of IBD therapies
AUSTIN, Texas — Inflammatory bowel disease can vary drastically from patient to patient. There is not a one-size-fits-all therapy that can handle all that variance. At the Crohn’s and Colitis Congress, experts provided an overview of the numerous IBD therapies to provide the attending physicians with some baseline knowledge before they started with the scientific sessions.